All Updates

All Updates

icon
Filter
Partnerships
Tempus AI collaborates with United Therapeutics to develop AI-based risk detection for pulmonary hypertension
Precision Medicine
Jun 25, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 25, 2024

Tempus AI collaborates with United Therapeutics to develop AI-based risk detection for pulmonary hypertension

Partnerships

  • Tempus AI has partnered with United Therapeutics to develop medical device software that uses AI to detect early-stage pulmonary hypertension (PH).

  • The partnership expects to study the use of AI to identify individuals at risk of undiagnosed PH via analysis of electrocardiogram results. Tempus' AI-powered care pathway intelligence solution, Tempus Next, will be used in the deployment process for a prospective clinical study, conducted among 60 selected centers. During the study, clinicians will evaluate the product’s ability to detect patients at risk of undiagnosed PH and track clinical outcomes of patients identified for further evaluation. The study aims to provide novel solutions to expedite diagnosis and enhance patient outcomes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.